AbbVie Inc.

艾伯维NYSE: ABBV

Biopharma · Immunology & Oncology · US-listed

Global diversified biopharmaceutical company (Humira, Skyrizi, Rinvoq, Botox, Juvederm).

Official investor relations ↗stock.hika.fyi deep-dive review ↗

Filings

Quarterly results press releaseQuarter ended Jun 30, 2026 (Q2 2026)Filed 2026-07-31

AbbVie Q2 2026 Results Press Release (8-K Exhibit 99.1)

Q2 net revenues $16.99B (+10.2% reported, +9.5% operational), GAAP diluted EPS $2.03 (+290.4%), adjusted EPS $3.65 (+22.9%, incl. -$0.17 IPR&D impact). Raised FY26 adjusted EPS guidance to $13.87-14.07.

Net revenues: $16.99B (+10.2% reported, +9.5% operational)GAAP diluted EPS: $2.03 (+290.4% YoY)Adjusted diluted EPS: $3.65 (+22.9% YoY, incl. -$0.17 IPR&D)FY26 guidance: Adjusted EPS $13.87-14.07 (incl. -$0.14 Apogee dilution)

Read original (EN)中文全文

Where to download AbbVie Inc. filings

US filings live on SEC EDGAR: annual reports (10-K), quarterly reports (10-Q) and earnings press releases (8-K Exhibit 99.1) are all in the company EDGAR archive; each filing page above links to the exact filing. You can also check the investor relations page.